Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global phase III study to evaluate rivaroxaban in patients with embolic stroke of undetermined source (ESUS)

Trial Profile

A global phase III study to evaluate rivaroxaban in patients with embolic stroke of undetermined source (ESUS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NAVIGATE ESUS
  • Most Recent Events

    • 05 Sep 2014 New trial record
    • 29 Aug 2014 Janssen may seek FDA approval for acute coronary syndrome, embolic stroke of undetermined source and peripheral artery disease indications, if these studies are successful.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top